The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Kevan M. Shokat(Howard Hughes Medical Institute)
Cited by 389
Related Papers
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
|PLoS Biology|2009|1.1k
Mechanistic Link between PKR Dimerization, Autophosphorylation, and eIF2α Substrate Recognition
|Cell|2005|367
Formin Leaky Cap Allows Elongation in the Presence of Tight Capping Proteins
|Current Biology|2003|265